A. F. Shields
A. F. Shields publishes mostly in Oncology, Pulmonary and Respiratory Medicine and Surgery, on topics such as Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations and Genetic factors in colorectal cancer.
- World rank
- #5,458,682 of 7,710,434 ranked researchers
- Rank in United States
- #1,379,320 of 1,627,098
- Works
- 27
- Citations
- 404
- Citations per work
- 15.0
What does A. F. Shields research?
A. F. Shields's work is mostly in Medicine (67%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1867.1%
- Medicine1867.1%
- Everything else932.9%
- 1Oncology27% of their works
- 2Pulmonary and Respiratory Medicine16% of their works
- 3Surgery10% of their works
- 4Pathology and Forensic Medicine6% of their works
- 5Public Health, Environmental and Occupational Health4% of their works
- 6Genetics4% of their works
Research topics
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Colorectal Cancer Surgical Treatments
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
Which keywords describe A. F. Shields's research?
The keywords of their largest research topics: Chemotherapy, Cetuximab, KRAS Mutations, Targeted Therapy, Adjuvant Chemotherapy, ALK Inhibitors, EGFR Mutations and Molecular Characterization.
- Cancer Genomics
- Rectal Cancer
- Myelofibrosis
- Gastric Cancer
- Chemotherapy-Induced Peripheral Neuropathy
- Hereditary Syndromes
- Molecular Characterization
- Adjuvant Chemotherapy
- Targeted Therapy
- Cetuximab
- Chemotherapy
- KRAS Mutations
- ALK Inhibitors
- EGFR Mutations
- Clinical Practice Guidelines
- Microsatellite Instability
- Endoscopic Resection
- JAK2 Mutation
- Preoperative Chemoradiotherapy
- Taxanes
- Mutational Signatures
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Chemotherapy142 topics
- Cetuximab111 topic
- KRAS Mutations111 topic
- Targeted Therapy92 topics
- ALK Inhibitors71 topic
- Adjuvant Chemotherapy72 topics
- EGFR Mutations71 topic
- Molecular Characterization72 topics
- Clinical Practice Guidelines62 topics
- Hereditary Syndromes41 topic
- Microsatellite Instability41 topic
- Chemotherapy-Induced Peripheral Neuropathy31 topic
- Endoscopic Resection31 topic
- Gastric Cancer31 topic
- JAK2 Mutation31 topic
- Myelofibrosis31 topic
- Preoperative Chemoradiotherapy31 topic
- Rectal Cancer31 topic
- Taxanes31 topic
- Cancer Genomics21 topic
- Mutational Signatures21 topic
Where does A. F. Shields work?
A. F. Shields's main affiliation in the publication record is Adelphi Laboratory Center, United States.
How many publications and citations does A. F. Shields have?
OpenAlex counts 27 works and 404 citations for A. F. Shields, an h-index of 6, ranking #5,458,682 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about A. F. Shields. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.